Martin MacKay, EVP & Global Head of R&D at ALEXION PHARMACEUTICALS INC (ALXN), sold 9,375 shares at $191.52 ($1.8M) on 2014-11-03, disclosed to the SEC on 2014-11-04.
Open-market sale of $1.8M ALXN by EVP & Global Head of R&D. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| Filing → |
| ALXN | SELL | 2017-02-10 | $28K | — | Filing → |
| ALXN | SELL | 2017-02-08 | $684K | — | Filing → |
| ALXN | SELL | 2016-05-18 | $1.1M | — | Filing → |